Allergan
Clinical trials sponsored by Allergan, explained in plain language.
Allergan, now part of AbbVie, develops pharmaceuticals in aesthetics, eye care, and neuroscience.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New filler gel aims to restore youthful cheeks
Symptom relief CompletedThis study tested an injectable gel called HArmonyCa lidocaine for filling out the mid face area in adults. About 171 participants were split into two groups: one received the gel right away, the other waited 3 months. Researchers checked for side effects and how well the gel imp…
Phase 3 • Sponsor: Allergan • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New frown line injection shows promise in early trial
Symptom relief CompletedThis study tested a new botulinum toxin injection (OnabotulinumtoxinA X) for treating moderate to severe frown lines between the eyebrows. 328 adults received either the active injection or a placebo. Researchers measured wrinkle improvement and tracked any side effects. The goal…
Phase 2 • Sponsor: Allergan • Aim: Symptom relief
Last updated Jun 26, 2026 15:01 UTC